Investing in innovation: The relationship between R&D spending and financial performance in the European pharmaceutical industry
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28120%2F23%3A63565518" target="_blank" >RIV/70883521:28120/23:63565518 - isvavai.cz</a>
Výsledek na webu
<a href="https://ieeca.org/journal/index.php/JEECAR/article/view/1368" target="_blank" >https://ieeca.org/journal/index.php/JEECAR/article/view/1368</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.15549/jeecar.v10i7.1368" target="_blank" >10.15549/jeecar.v10i7.1368</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Investing in innovation: The relationship between R&D spending and financial performance in the European pharmaceutical industry
Popis výsledku v původním jazyce
The pharmaceutical industry is highly capital and knowledge-intensive, spending approximately 15% of its total revenue on research and development (R&D). This study aims to find the relationship between pharmaceutical businesses' financial performance and investments made in drug research and development in Europe. The study employs regression analysis with a time-lag effect of R&D spending on operating earnings. It is hypothesised that the investment expenditure of the previous year’s R&D investment will significantly and concurrently impact the economic-financial performance of the country and the findings show a strong and positive link between the previous year’s R&D expenditure and the current year's operating profit in the European countries, providing convincing evidence that R&D investments will pay off financially in the years ahead for the development of pharmaceuticals. The study also conducted diagnosis tests for the validation of the estimated models.
Název v anglickém jazyce
Investing in innovation: The relationship between R&D spending and financial performance in the European pharmaceutical industry
Popis výsledku anglicky
The pharmaceutical industry is highly capital and knowledge-intensive, spending approximately 15% of its total revenue on research and development (R&D). This study aims to find the relationship between pharmaceutical businesses' financial performance and investments made in drug research and development in Europe. The study employs regression analysis with a time-lag effect of R&D spending on operating earnings. It is hypothesised that the investment expenditure of the previous year’s R&D investment will significantly and concurrently impact the economic-financial performance of the country and the findings show a strong and positive link between the previous year’s R&D expenditure and the current year's operating profit in the European countries, providing convincing evidence that R&D investments will pay off financially in the years ahead for the development of pharmaceuticals. The study also conducted diagnosis tests for the validation of the estimated models.
Klasifikace
Druh
J<sub>SC</sub> - Článek v periodiku v databázi SCOPUS
CEP obor
—
OECD FORD obor
50204 - Business and management
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Eastern European and Central Asian Research
ISSN
2328-8272
e-ISSN
2328-8280
Svazek periodika
10
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
21
Strana od-do
10006-1026
Kód UT WoS článku
001124558100001
EID výsledku v databázi Scopus
2-s2.0-85179948358